Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD 4 Ig SF coadministration PD1 MS SDSPAGE Val 29 CD 223
- Product Overview:
Lymphocyte activation gene 3 (LAG-3) protein is a CD4-like protein and member of the immunoglobulin superfamily (IgSF) that binds with high affinity to MHC class II molecules.{56111,56112} LAG3 is expressed in activated T cells and natural killer cells, and the protein functions as an inhibitory co-receptor that modulates T cell homeostasis, proliferation, expansion, activation, and function.{56113,56114,56112} LAG-3 is comprised of an N-terminal extracellular domain with four IgSF domains, a transmembrane domain, and a C-terminal cytoplasmic domain with a KIEELE motif required for modulation of T cell function.{56111,56113,56112} Elevated LAG3 expression in chronic lymphocytic leukemia (CLL) cells is associated with reduced treatment-free survival in patients with CLL.{56115} Co-administration of antibodies against both LAG-3 and PD-1 (Item No. 28377) reduces the number and percentage of CLL cells in blood and spleen in a CLL-splenocyte adoptive transfer mouse model.{56116} SNPs in LAG3 are associated with susceptibility to multiple sclerosis.{56117} Cayman’s LAG-3 Extracellular Domain (human, recombinant) protein consists of 433 amino acids, has a calculated molecular weight of 47 kDa, and a predicted N-terminus of Val29 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 50 to 60 kDa due to glycosylation.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.